ret fusion-positive nsclc: delivering targeted treatment | panel discussion
Published 2 years ago • 794 plays • Length 27:47Download video MP4
Download video MP3
Similar videos
-
7:20
arrow points the way for ret fusion-positive nsclc treatment | stephen liu
-
3:18
arrow update confirms pralsetinib benefit for ret fusion-positive advanced nsclc | stephen liu
-
19:18
alk fusion-positive nsclc: international approaches to management | panel discussion
-
37:34
managing ros1 fusion-positive nsclc in europe and the usa | panel discussion
-
3:49
ret fusion treatment: selpercatinib - targeted therapies in lung cancer 2023
-
1:48
selpercatinib induced durable efficacy in ret fusion-positive nsclc
-
7:37
rare fusions in nsclc: ret - targeted therapies in lung cancer 2023
-
2:12
the impact of selpercatinib in patients with ret fusion-positive nsclc
-
4:58
treatment of nsclc with ret fusions
-
9:57
expert highlights: targeted therapy for alk-, ret- and met-driven nsclc | tejas patil
-
6:59
targeted therapy for treatment-naïve ret fusion-positive lung cancers
-
2:48
ret fusion-positive mnsclc: selpercatinib and pralsetinib
-
1:14:14
fine-tuning biomarker testing to identify and target ret fusions in nsclc
-
6:40:28
full video ondemand -targeted therapies patient forum 2022 - for those living with lung cancer
-
6:52
emerging agents and combinations to treat ret fusion-positive lung cancers
-
2:49
treatments for ret nsclc: selpercatinib vs. pralsetinib - 2022 program: targeted therapies forum
-
3:58
highlights on selpercatinib in ret fusion-positive nsclc: the libretto-431 study
-
5:06
libretto-001: ret-fusion positive metastatic nsclc
-
28:43
macrocyclic tkis in treatment-naïve and pretreated fusion-positive nsclc and other tumors